Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Orchestra BioMed Holdings (NASDAQ:OBIO) and maintained a price target of $20.
August 09, 2023 | 8:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Orchestra BioMed Holdings and maintained a price target of $20.
The reiteration of a 'Buy' rating by Chardan Capital indicates their continued confidence in Orchestra BioMed Holdings. The maintained price target of $20 suggests that they believe the stock is still undervalued. This could potentially lead to increased investor interest and a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100